Scrip
Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.
Scrip
Agreeing that decentralized trials are here to stay, experts discussed in a recent meeting ways in which the pharma research landscape is set to change. With nearly 85% of the industry at different stages of adoption, such trials have seen greater traction in the US, while stricter data privacy laws have hampered progress in Europe, ISCR’s annual conference heard.
Scrip
Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.
Topic Business Strategies China Company Analysis Drug Development Landscape Market Intelligence
Scrip
Based in Cambridge UK, Dunad believes it has developed a platform which is "tuneable and highly selective" and represents a new and differentiated targeted protein degradation approach.
Scrip
In this week's podcast version of Five Must-Know Things, hear about new results for Lilly in Alzheimer’s, a US delay for AbbVie, progress for Zolgensma in the UK, challenges for AstraZeneca’s coronavirus vaccine, and a Scrip roundtable on industry lessons from the pandemic.
Biomedtracker, Scrip
Keep up with events as they unfold at the 39th Annual J.P. Morgan Annual Healthcare Conference on January 11-14, 2021. Pharma Intelligence and Insights journalists will bring you real time reporting, highlighting important events and key takeaways from every day of the largest and most informative healthcare investment symposium in the industry.
Scrip
Company suspends enrolment to trials as coronavirus travel restrictions bite.
Topic Coronavirus
Scrip
The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with.
Scrip
Comment: While the travails around the COVID-19 vaccine continue, AstraZeneca has plenty in its pipeline to cheer investors.
Scrip
Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.
Scrip
In this week's podcast version of Five Must-Know Things, hear about Roche's deal-making in a pandemic, coronavirus vaccine disinformation, Amgen’s Five Prime acquisition, a Novartis clinical trial failure, and new data for a Merck antiviral for the coronavirus.
Scrip
Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.
Scrip
China, Iran and especially Russia have launched campaigns aimed at undermining confidence in Western vaccines, especially Pfizer’s, according to two reports.
Scrip
The US company is poised to file with regulators in Q2, but is also looking for longer-term competitive advantage in its variant strategy.
Scrip
Looking back at the deal landscape of 2020, large-scale deals were overtaken by smaller transactions, though volume was up, driven by pandemic-related business.
Scrip
16 Apr 2021
Scrip
16 Apr 2021
Scrip
16 Apr 2021
Scrip
16 Apr 2021
Scrip
16 Apr 2021
Scrip
16 Apr 2021
Scrip
15 Apr 2021
Scrip
15 Apr 2021
Scrip
15 Apr 2021
Scrip
15 Apr 2021
Scrip
15 Apr 2021
Scrip
15 Apr 2021
Scrip
15 Apr 2021
Scrip
14 Apr 2021
Scrip
14 Apr 2021
New York, USA
Brenda specializes in
+39 year(s) experience
Washington DC, USA
Cathy specializes in
+39 year(s) experience
Washington DC, USA
Denise specializes in
+38 year(s) experience
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: